Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT02990936 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy

TGV-PI
Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this study is to determine the impact of tumor growth velocity on the survival of patients with hea and neck squamous cell carcinoma treated by (chemo-)radiotherapy. Patients with stages I to IV oropharyngeal primary squamous cell carcinoma (OPSCC) elected for radiotherapy or radiochemotherapy with curative intent will be selected. Tumor volume and number and size of pathological neck lymph nodes (small diameter > 1 cm) will be assessed on diagnostic CT-scan (DiCT) and treatment planning CT-scan (RtCT) using the summation of areas technique. Tumor progression and tumor doubling time will be calculated based on DiCT and RtCT. Tumor proliferation will be assessed on biopsy specimens by Ki67 immunohistochemistry and mitotic index. HPV status will be evaluated by PCR and p16 immunohistochemistry. Ulcerative or exophytic aspect will be noticed. Tumoral kinetics patterns will be correlated with disease free survival and overall survival of patients with HNSCC. These patterns will be compared to HPV status and proliferation markers in order to study their clinical signification [time frame: 5 years] and develop predictive markers of tumor progression for head and neck cancers.

NCT ID: NCT02851264 Not yet recruiting - Clinical trials for Early Esophageal Squamous Neoplasia

Diagnostic Value of Optical Enhancement Technology in Early Esophageal Squamous Neoplasia

Start date: August 2016
Phase: N/A
Study type: Observational

The aims of the present study: 1. To investigate the diagnosing value of optical enhancement technology for early esophageal squamous neoplasia. 2. To assess the detection rate of early esophageal squamous neoplasia by virtual chromoendoscopy with optical enhancement technology .

NCT ID: NCT02806557 Not yet recruiting - Neoplasms Clinical Trials

Profiling Neutrophil Counts in Patients on Chemotherapy

Start date: September 2016
Phase: N/A
Study type: Observational

The purpose of this trial is to observe the changes in white cell counts in patients with cancer during chemotherapy and to determine if changes in the white cell count in the early days during chemotherapy can be used as a predictor of severe neutropenia and its complications.

NCT ID: NCT02758977 Not yet recruiting - Surgery Clinical Trials

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)

ALPPSforCRLM
Start date: May 2016
Phase: N/A
Study type: Interventional

Surgical resection has offered the best option for prolonged survival in patients with colorectal liver metastases. Limiting factor for major liver resections is the size of the future liver remnant (FLR). In case of normal liver function, 30% of the total liver volume is considered to be sufficient to maintain adequate liver function after resection. In an attempt to further increase "resectability" criteria for patients with too small FLR surgical and interventional maneuvers such as portal vein embolization and portal vein ligation in two-stage hepatectomies have been implemented, but they need an interval of 4-8 weeks to achieve sufficient hypertrophy. In order to obtain adequate but rapid parenchymal hypertrophy a new surgical two-step technique, ALPPS, was introduced for oncological patients requiring extended hepatic resection with limited functional reserve. Both procedures can be performed with acceptable morbidity and mortality. The investigators conclude that it is time to perform a randomized study comparing the two surgical approaches in regard to oncological outcome.

NCT ID: NCT02747225 Not yet recruiting - Neoplasms Clinical Trials

Measuring the Electrical Properties of Malignant Tissues In Vivo

Start date: December 2018
Phase:
Study type: Observational [Patient Registry]

Previously published studies have indicated that there exist difference in electrical properties (EPs), i.e., the conductivity and relative permittivity, between malignant and adjacent normal tissue, which will be useful in the early detection of cancers. However the EP information mainly based on ex vivo measurement of cancer tissues, and few data in vivo were published. The purpose of this study is to in vivo measure the electrical properties of the malignant tissues.

NCT ID: NCT02747212 Not yet recruiting - Neoplasms Clinical Trials

Measuring the Electrical Properties of Malignant Tissues Ex Vivo

Start date: December 1, 2018
Phase:
Study type: Observational

Previously published studies have indicated that there exist difference in electrical properties (EPs), i.e., the conductivity and relative permittivity, between malignant and adjacent normal tissue, which will be useful in the early detection of cancers. While the EP informations of cancer tissues are not sufficient enough. The purpose of this study is to measure the electrical properties of the excised malignant tissues obtained from cancer surgeries.

NCT ID: NCT02647047 Not yet recruiting - Liver Diseases Clinical Trials

Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery

Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of spinal analgesia for minor laparotomic hepatectomy compared with epidural analgesia, monitoring visual analog scale (VAS). The investigators expect at least the same post-operative pain control in the two groups (non inferiority of pain control with spinal analgesia compared to epidural analgesia). Second endpoint is to verify whether after spinal analgesia there is a decrease in patient's length of hospitalization according to enhanced recovery after surgery (ERAS) principles.

NCT ID: NCT02622620 Not yet recruiting - Neoplasms Clinical Trials

Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques

Start date: July 2016
Phase: N/A
Study type: Observational

Contrast-enhanced MRI is the most common way for evaluating neuroepithelial tumor grading and monitoring for tumor recurrence,but the ability to predict tumor behavior remains very limited.In this study, the investigators will use multi-b-value diffusion-weighted imaging(DWI),three-dimensional arterial spin labeling(3D-ASL) and dynamic contrast-enhanced MRI imaging(DCE) to evaluate neuroepithelial tumor grading and monitor for tumor recurrence.

NCT ID: NCT02600481 Not yet recruiting - Prostatic Neoplasms Clinical Trials

Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery

Start date: January 2016
Phase: N/A
Study type: Interventional

This study is aimed to determine whether low- and standard-pressure pneumoperitoneum have different impacts on troponin T(TnT) level as well as pulmonary complications after prolonged robot-assisted surgeries in the Trendelenburg position.

NCT ID: NCT02478476 Not yet recruiting - Ovarian Neoplasms Clinical Trials

DNA Single Nucleotide Polymorphisms as Predictors of Toxicity

Start date: July 2015
Phase: N/A
Study type: Observational

The presence of single nucleotide polymorphisms (SNPs) in genes involved in platinum and taxane metabolism and detoxification have been correlated to increased risk of severe adverse events (AEs) when patients receive these drugs. The investigators propose studies to validate a comprehensive panel of twelve SNPs in ovarian cancer patients that may predict AEs when treated with therapies that include platinum and taxanes. Using these results to stratify patients to different dosing regimens, routes of administration, or in recurrent cancer to aid in drug selection, may improve outcome and reduce costs for the management of drug related side effects while not changing standard of care. Since these differences can be detected from blood, the determination of genotypes can be done using a standard blood sample taken after ovarian cancer is confirmed on the patient's pathology report. These genetic differences can be detected by QPCR and Next Generation Sequencing.